Loading resource…

Graecia University
Inclisiran has recently been approved by regulatory agencies due to its efficacy and safety in treating dyslipidemias. The review discusses the established link between LDL-cholesterol and atherosclerotic cardiovascular disease (ASCVD), emphasizing inclisiran's role as a promising therapeutic tool. It provides insights into ongoing trials and future perspectives for its implementation in clinical practice.
No account needed